| Heterogeneity of tumor and immune cell PD-L1 expression and lymphocyte counts in surgical NSCLC samples D Casadevall, S Clavé, Á Taus, M Hardy-Werbin, P Rocha, M Lorenzo, ... Clinical lung cancer 18 (6), 682-691. e5, 2017 | 87 | 2017 |
| Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer M Hardy-Werbin, P Rocha, O Arpi, Á Taus, L Nonell, X Durán, ... Oncoimmunology 8 (6), e1593810, 2019 | 58 | 2019 |
| Dynamics of EGFR mutation load in plasma for prediction of treatment response and disease progression in patients with EGFR-mutant lung adenocarcinoma Á Taus, L Camacho, P Rocha, M Hardy-Werbin, L Pijuan, G Piquer, ... Clinical Lung Cancer 19 (5), 387-394. e2, 2018 | 49 | 2018 |
| CD103+ CD8+ lymphocytes characterize the immune infiltration in a case with pseudoprogression in squamous NSCLC P Rocha, M Hardy-Werbin, D Naranjo, Á Taus, M Rodrigo, F Zuccarino, ... Journal of Thoracic Oncology 13 (10), e193-e196, 2018 | 40 | 2018 |
| Pretreatment tissue TCR repertoire evenness is associated with complete pathologic response in patients with NSCLC receiving neoadjuvant chemoimmunotherapy M Casarrubios, A Cruz-Bermúdez, E Nadal, A Insa, MR García Campelo, ... Clinical Cancer Research 27 (21), 5878-5890, 2021 | 37 | 2021 |
| Pancreatitis with vascular endothelial growth factor receptor tyrosine kinase inhibitors P Ghatalia, CJ Morgan, TK Choueiri, P Rocha, G Naik, G Sonpavde Critical Reviews in Oncology/Hematology 94 (1), 136-145, 2015 | 35 | 2015 |
| Next-Generation sequencing for ALK and ROS1 rearrangement detection in patients with Non–small-cell lung cancer: implications of FISH-positive patterns S Clavé, N Rodon, L Pijuan, O Díaz, M Lorenzo, P Rocha, Á Taus, ... Clinical lung cancer 20 (4), e421-e429, 2019 | 34 | 2019 |
| Assessment of neuronal autoantibodies in patients with small cell lung cancer treated with chemotherapy with or without ipilimumab M Hardy-Werbin, O Arpí, A Taus, P Rocha, D Joseph-Pietras, L Nolan, ... Oncoimmunology 7 (2), e1395125, 2018 | 30 | 2018 |
| Prognostic impact of C-reactive protein in metastatic prostate cancer: a systematic review and meta-analysis P Rocha, CJ Morgan, AJ Templeton, GR Pond, G Naik, G Sonpavde Oncology Research and Treatment 37 (12), 772-776, 2014 | 27 | 2014 |
| CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma P Rocha, R Salazar, J Zhang, D Ledesma, JL Solorzano, B Mino, ... Cancer Immunology, Immunotherapy 70, 1965-1976, 2021 | 23 | 2021 |
| Concomitant genomic alterations in KRAS mutant advanced lung adenocarcinoma J Gibert, S Clavé, M Hardy-Werbin, Á Taus, P Rocha, R Longarón, ... Lung Cancer 140, 42-45, 2020 | 17 | 2020 |
| Female gender predicts augmented immune infiltration in lung adenocarcinoma C Behrens, P Rocha, ER Parra, L Feng, J Rodriguez-Canales, LM Solis, ... Clinical Lung Cancer 22 (3), e415-e424, 2021 | 14 | 2021 |
| Distinct immune gene programs associated with host tumor immunity, neoadjuvant chemotherapy, and chemoimmunotherapy in resectable NSCLC P Rocha, J Zhang, R Laza-Briviesca, A Cruz-Bermúdez, ... Clinical Cancer Research 28 (11), 2461-2473, 2022 | 11 | 2022 |
| The transcriptomic landscape of mismatch repair-deficient intestinal stem cells PV Bommi, CM Bowen, L Reyes-Uribe, W Wu, H Katayama, P Rocha, ... Cancer research 81 (10), 2760-2773, 2021 | 10 | 2021 |
| Dynamic expression of Schlafen 11 (SLFN11) in circulating tumour cells as a liquid biomarker in small cell lung cancer B Zhang, CA Stewart, Q Wang, RJ Cardnell, P Rocha, J Fujimoto, ... British journal of cancer 127 (3), 569-576, 2022 | 9 | 2022 |
| Comparison of different methods for defining hyperprogressive disease in NSCLC P Rocha, D Ramal, E Ripoll, L Moliner, A Corbera, M Hardy-Werbin, ... JTO Clinical and Research Reports 2 (1), 100115, 2021 | 7 | 2021 |
| Plasmatic KRAS kinetics for the prediction of treatment response and progression in patients with KRAS-mutant lung adenocarcinoma Á Taus, L Camacho, P Rocha, A Hernández, R Longarón, S Clavé, ... Archivos de Bronconeumología (English Edition) 57 (5), 323-329, 2021 | 6 | 2021 |
| Immunotherapy is Here to Stay: a new treatment paradigm in lung cancer PP Rocha, E Arriola Aperribay Archivos de Bronconeumología. 2019 Mar; 55 (3): 124-5, 2019 | 5 | 2019 |
| Analysis of Immune Intratumor Heterogeneity Highlights Immunoregulatory and Coinhibitory Lymphocytes as Hallmarks of Recurrence in Stage I Non–Small Cell Lung Cancer A Francisco-Cruz, P Rocha, A Reuben, SN Krishnan, P Das, R Chen, ... Modern Pathology 36 (1), 100028, 2023 | 4 | 2023 |
| Identification of MET gene amplifications using next-generation sequencing in non-small cell lung cancer patients S Clavé, M Salido, P Rocha, M Hardy-Werbin, J Gibert, X Riera, ... Annals of Oncology 30, v800, 2019 | 4 | 2019 |
